Lilly forecasts weak sales of weight-loss drug in fourth quarter
1. Eli Lilly forecasts 2025 revenue surpassing estimates despite Q4 sales misses. 2. Weight-loss drug Zepbound and Mounjaro projected to fall short of expectations.
FAQ
Why Neutral?
Revenue outlook above estimates is positive, but Q4 misses could weigh on sentiment.
How important is it?
Sales expectations impact investor sentiment, reflecting on stock performance.
Why Short Term?
Immediate Q4 results could lead to volatility, but 2025 outlook is favorable.